Search results for "blood–brain barrier"

showing 10 items of 134 documents

Amphiphilic HPMA-LMA copolymers increase the transport of Rhodamine 123 across a BBB model without harming its barrier integrity.

2012

Abstract The successful non-invasive treatment of diseases associated with the central nervous system (CNS) is generally limited by poor brain permeability of various developed drugs. The blood–brain barrier (BBB) prevents the passage of therapeutics to their site of action. Polymeric drug delivery systems are promising solutions to effectively transport drugs into the brain. We recently showed that amphiphilic random copolymers based on the hydrophilic p(N-(2-hydroxypropyl)-methacrylamide), pHPMA, possessing randomly distributed hydrophobic p(laurylmethacrylate), pLMA, are able to mediate delivery of domperidone into the brain of mice in vivo. To gain further insight into structure–propert…

Drug CarriersPharmaceutical SciencePolymer architectureBiological TransportPharmacologyBlood–brain barrierRhodamine 123Models BiologicalPermeabilityCell Linechemistry.chemical_compoundmedicine.anatomical_structurechemistryTranscytosisIn vivoBlood-Brain BarrierNanoparticles for drug delivery to the brainAmphiphilemedicineHumansMethacrylatesRhodamine 123Barrier functionFluorescent DyesJournal of controlled release : official journal of the Controlled Release Society
researchProduct

Potential of biopartitioning micellar chromatography as an in vitro technique for predicting drug penetration across the blood–brain barrier

2004

The blood-brain barrier (BBB) is considered to be the main barrier to drug transport into the central nervous system (CNS). The BBB restricts the passive diffusion of many drugs from blood to brain. The ease with which any particular drug diffuses across the BBB is determined largely by the molecular features of drugs, and it is therefore possible to predict the BBB permeability of a drug from its molecular structure. Biopartitioning micellar chromatography (BMC), a mode of micellar liquid chromatography that uses micellar mobile phases of Brij35 in adequate experimental conditions, can be useful in mimicking the drug partitioning process into biological systems. Retention in BMC depends on…

DrugChromatographyChemistrymedia_common.quotation_subjectClinical BiochemistryCell BiologyGeneral MedicinePenetration (firestop)In Vitro TechniquesModels TheoreticalBlood–brain barrierDrug penetrationBiochemistryIn vitroAnalytical ChemistryPartition coefficientmedicine.anatomical_structureBlood-Brain BarrierMicellar liquid chromatographymedicineRegression AnalysisChromatography Liquidmedia_commonDrug transportJournal of Chromatography B
researchProduct

Amphiphilic Copolymers Shuttle Drugs Across the Blood-Brain Barrier.

2015

Medical treatment of diseases of the central nervous system requires transport of drugs across the blood-brain barrier (BBB). Here, it is extended previously in vitro experiments with a model compound to show that the non-water-soluble and brain-impermeable drug domperidone (DOM) itself can be enriched in the brain by use of an amphiphilic copolymer as a carrier. This carrier consists of poly(N-(2-hydroxypropyl)-methacrylamide), statistically copolymerized with 10 mol% hydrophobic lauryl methacrylate, into whose micellar aggregates DOM is noncovalently absorbed. As tested in a BBB model efficient transport of DOM across, the BBB is achievable over a wide range of formulations, containing 0.…

DrugPolymers and PlasticsPolymersmedia_common.quotation_subjectmedicine.medical_treatmentIntraperitoneal injectionBioengineering02 engineering and technologyPharmacology010402 general chemistryBlood–brain barrier01 natural sciencesMicelleBiomaterialsMiceDrug Delivery SystemsIn vivoCentral Nervous System DiseasesMaterials ChemistrymedicineAnimalsHumansMicellesmedia_commonChromatographyChemistry021001 nanoscience & nanotechnologyIn vitroDomperidone0104 chemical sciencesDomperidonemedicine.anatomical_structureBlood-Brain BarrierDrug deliveryMethacrylates0210 nano-technologyBiotechnologymedicine.drugMacromolecular bioscience
researchProduct

A Neurovascular Blood–Brain Barrier In Vitro Model

2014

The cerebral microvasculature possesses certain cellular features that constitute the blood-brain barrier (BBB) (Abbott et al., Neurobiol Dis 37:13-25, 2010). This dynamic barrier separates the brain parenchyma from peripheral blood flow and is of tremendous clinical importance: for example, BBB breakdown as in stroke is associated with the development of brain edema (Rosenberg and Yang, Neurosurg Focus 22:E4, 2007), inflammation (Kuhlmann et al., Neurosci Lett 449:168-172, 2009; Coisne and Engelhardt, Antioxid Redox Signal 15:1285-1303, 2011), and increased mortality. In vivo, the BBB consists of brain endothelial cells (BEC) that are embedded within a precisely regulated environment conta…

EndotheliumTight junctionInflammationAnatomyBiologyBlood–brain barriermedicine.anatomical_structureIn vivoLive cell imagingCortical spreading depressionmedicineNeuronmedicine.symptomNeuroscience
researchProduct

P-Glycoprotein Influence on the Brain Uptake of a 5-HT2A Ligand: [18F]MH.MZ

2010

<i>Background/Aims:</i> The serotonergic system, especially the 5-HT<sub>2A</sub> receptor, is involved in various diseases and conditions. We have recently developed a new [<sup>18</sup>F]-5-HT<sub>2A</sub> receptor ligand using an analogue, MDL 100907, as a basis for molecular imaging with positron emission tomography. This tracer, [<sup>18</sup>F]MH.MZ, has been shown to be an adequate tool to visualize the 5-HT<sub>2A</sub> receptors in vivo. However, [<sup>18</sup>F]altanserin, similar in chemical structure, is a substrate of efflux transporters, such as P-glycoprotein (P-gp), of the blood-brain barrier…

Fluorine RadioisotopesPharmacologyBiologySerotonergicBlood–brain barrierMicePiperidinesPharmacokineticsCerebellummedicineAnimalsReceptor Serotonin 5-HT2AATP Binding Cassette Transporter Subfamily B Member 1ReceptorBiological PsychiatryP-glycoproteinMice KnockoutBrain uptakeBiological TransportLigand (biochemistry)Frontal LobeFluorobenzenesPsychiatry and Mental healthNeuropsychology and Physiological Psychologymedicine.anatomical_structureBlood-Brain BarrierPositron-Emission Tomographybiology.proteinNeuroscienceNeuropsychobiology
researchProduct

Nitric Oxide/Cyclic Guanosine Monophosphate Signaling via Guanylyl Cyclase Isoform 1 Mediates Early Changes in Synaptic Transmission and Brain Edema …

2021

Traumatic brain injury (TBI) often induces structural damage, disruption of the blood-brain barrier (BBB), neurodegeneration, and dysfunctions of surviving neuronal networks. Nitric oxide (NO) signaling has been suggested to affect brain functions after TBI. The NO exhibits most of its biological effects by activation of the primary targets-guanylyl cyclases (NO-GCs), which exists in two isoforms (NO-GC1 and NO-GC2), and the subsequently produced cyclic guanosine monophosphate (cGMP). However, the specific function of the NO-NO-GCs-cGMP pathway in the context of brain injury is not fully understood. To investigate the specific role of the isoform NO-GC1 early after brain injuries, we perfor…

Gene isoform030506 rehabilitationTraumatic brain injuryBrain EdemaReceptors Cell SurfaceNeurotransmissionBlood–brain barrierNitric OxideSynaptic TransmissionNitric oxide03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicineBrain Injuries TraumaticmedicinePremovement neuronal activityAnimalsCyclic guanosine monophosphateCyclic GMPMice KnockoutNeurodegenerationSomatosensory Cortexmedicine.diseaseIsoenzymesmedicine.anatomical_structurenervous systemchemistryGuanylate CyclaseNeurology (clinical)0305 other medical scienceNeuroscience030217 neurology & neurosurgerySignal TransductionJournal of neurotrauma
researchProduct

A Novel 1,4-Dihydropyridine Derivative Improves Spatial Learning and Memory and Modifies Brain Protein Expression in Wild Type and Transgenic APPSweD…

2015

Ca2+ blockers, particularly those capable of crossing the blood-brain barrier (BBB), have been suggested as a possible treatment or disease modifying agents for neurodegenerative disorders, e.g., Alzheimer's disease. The present study investigated the effects of a novel 4-(N-dodecyl) pyridinium group-containing 1,4-dihydropyridine derivative (AP-12) on cognition and synaptic protein expression in the brain. Treatment of AP-12 was investigated in wild type C57BL/6J mice and transgenic Alzheimer's disease model mice (Tg APPSweDI) using behavioral tests and immunohistochemistry, as well as mass spectrometry to assess the blood-brain barrier (BBB) penetration. The data demonstrated the ability …

Genetically modified mouseMalePathologymedicine.medical_specialtyDihydropyridinesTime Factorsmedicine.drug_classTransgeneSpatial Learninglcsh:MedicineMice TransgenicBlood–brain barrierAnxiolyticGyrus CinguliHippocampus03 medical and health sciences0302 clinical medicineHomer Scaffolding ProteinsMemorymedicineAnimalsHumanslcsh:Science030304 developmental biology0303 health sciencesMultidisciplinaryAmyloid beta-PeptidesGlutamate Decarboxylaselcsh:RDihydropyridineWild typeBrainmedicine.disease3. Good healthMice Inbred C57BLmedicine.anatomical_structureAnti-Anxiety AgentsBlood-Brain BarrierSynaptic plasticitylcsh:QAlzheimer's diseaseCarrier ProteinsNeuroscience030217 neurology & neurosurgerymedicine.drugResearch ArticlePloS one
researchProduct

The Complementary Membranes Forming the Blood-Brain Barrier

2002

Brain capillary endothelial cells form the blood-brain barrier. They are connected by extensive tight junctions, and are polarized into luminal (blood-facing) and abluminal (brain-facing) plasma membrane domains. The polar distribution of transport proteins allows for active regulation of brain extracellular fluid. Experiments on isolated membrane vesicles from capillary endothelial cells of bovine brain demonstrated the polar arrangement of amino acid and glucose transporters, and the utility of such arrangements have been proposed. For instance, passive carriers for glutamine and glutamate have been found only in the luminal membrane of blood-brain barrier cells, while Na-dependent second…

GlutamineClinical BiochemistryGlutamic AcidBiologyBlood–brain barrierBiochemistryAmmoniaExtracellular fluidGeneticsmedicineAnimalsHumansMolecular Biologychemistry.chemical_classificationTight junctionGlucose transporterCell BiologyAmino acidTransport proteinGlutamineGlucoseMembranemedicine.anatomical_structureBiochemistrychemistryBlood-Brain BarrierBiophysicsIUBMB Life (International Union of Biochemistry and Molecular Biology: Life)
researchProduct

Structure of the Blood–Brain Barrier and Its Role in the Transport of Amino Acids

2005

Brain capillary endothelial cells form the blood-brain barrier (BBB). They are connected by extensive tight junctions, and are polarized into luminal (blood-facing) and abluminal (brain-facing) plasma membrane domains. The polar distribution of transport proteins mediates amino acid (AA) homeostasis in the brain. The existence of two facilitative transporters for neutral amino acids (NAAs) on both membranes provides the brain access to essential AAs. Four Na(+)-dependent transporters of NAA exist in the abluminal membranes of the BBB. Together these systems have the capability to actively transfer every naturally occurring NAA from the extracellular fluid (ECF) to endothelial cells and from…

GlutamineGlutamic AcidMedicine (miscellaneous)Blood–brain barrierAmmoniaExtracellular fluidmedicineAnimalsHumansAmino Acidschemistry.chemical_classificationNutrition and DieteticsTight junctionChemistrySodiumGlutamate receptorBiological Transportgamma-GlutamyltransferasePyrrolidonecarboxylic AcidTransport proteinAmino acidGlutamineMembranemedicine.anatomical_structureBiochemistryBlood-Brain BarrierBiophysicsThe Journal of Nutrition
researchProduct

Mannitol in Amanita muscaria – An osmotic blood–brain barrier disruptor enhancing its hallucinogenic action?

2013

Hypothesis have been made that relatively high level of mannitol present in the tissues of fly agaric (Amanita muscaria) enables more efficient transportation of these active substances into the brain and thus enhance their total activity. It may have been supported by the fact that hallucinogenic effect after A. muscaria consumption is greater than after ingestion of an active substance quantity which the eaten fungi dose contain.

HallucinogenMagnetic Resonance SpectroscopyInjury controlAmanitaPoison controlComplex MixturesPharmacologyBlood–brain barrierToxicologyOsmoregulationSpecies SpecificityHumansMedicineIngestionMannitolbiologybusiness.industryAgaricBrainGeneral Medicinebiology.organism_classificationmedicine.anatomical_structureHallucinogensMannitolbusinessAmanita muscariamedicine.drugMedical Hypotheses
researchProduct